

## Psychiatric illness and regression in individuals with Phelan-McDermid syndrome

Teresa Kohlenberg, M. Pilar Trelles, Brittany Mclarney, Catalina Betancur,  
Audrey Thurm, Alexander Kolevzon

► **To cite this version:**

Teresa Kohlenberg, M. Pilar Trelles, Brittany Mclarney, Catalina Betancur, Audrey Thurm, et al..  
Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. *Journal of Neurodevelopmental Disorders*, BioMed Central, 2020, 12 (1), pp.7. 10.1186/s11689-020-9309-6 . inserm-02479574

**HAL Id: inserm-02479574**

**<https://www.hal.inserm.fr/inserm-02479574>**

Submitted on 14 Feb 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access



# Psychiatric illness and regression in individuals with Phelan-McDermid syndrome

Teresa M. Kohlenberg<sup>1\*</sup> , M. Pilar Trelles<sup>2,3</sup>, Brittany McLarney<sup>4</sup>, Catalina Betancur<sup>5</sup>, Audrey Thurm<sup>6</sup> and Alexander Kolevzon<sup>2,3</sup>

## Abstract

**Background:** Phelan-McDermid syndrome (PMS) is a genetic condition characterized by intellectual disability, speech and language deficits, hypotonia, autism spectrum disorder, and epilepsy. PMS is caused by 22q13.33 deletions or mutations affecting *SHANK3*, which codes for a critical scaffolding protein in excitatory synapses. *SHANK3* variants are also known to be associated with an increased risk for regression, as well as for psychiatric disorders, including bipolar disorder and catatonia. This study aimed to further describe these phenomena in PMS and to explore any relationship between psychiatric illness and regression after early childhood.

**Methods:** Thirty-eight people with PMS were recruited to this study through the Phelan-McDermid Syndrome Foundation based on caregiver report of distinct development of psychiatric symptoms. Caregivers completed a clinician-administered semi-structured interview focused on eliciting psychiatric symptomatology. Data from the PMS International Registry were used to confirm genetic diagnoses of participants and to provide a larger sample for comparison.

**Results:** The mean age of the 38 participants was 24.7 years (range = 13 to 50; SD = 10.06). Females (31 of 38 cases; 82%) and sequence variants (15 of 38 cases; 39%) were over-represented in this sample, compared to base rates in the PMS International Registry. Onset of psychiatric symptoms occurred at a mean age of 15.4 years (range = 7 to 32), with presentations marked by prominent disturbances of mood. Enduring substantial loss of functional skills after onset of psychiatric changes was seen in 25 cases (66%). Symptomst indicative of catatonia occurred in 20 cases (53%). Triggers included infections, changes in hormonal status, and stressful life events.

**Conclusions:** This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood, including bipolar disorder, catatonia, and lasting regression of skills. These findings should increase the awareness of these phenotypes and lead to earlier diagnosis and the implementation of appropriate interventions. Our findings also highlight the importance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric disorders and regression among larger unbiased samples of individuals with PMS.

**Keywords:** Phelan-McDermid syndrome, *SHANK3*, Mania, Depression, Bipolar disorder, Psychosis, Catatonia, Regression

\* Correspondence: [tesik@rcn.com](mailto:tesik@rcn.com)

<sup>1</sup>Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA

Full list of author information is available at the end of the article



## Background

Phelan-McDermid syndrome (PMS) is a neurogenetic syndrome caused by haploinsufficiency of the *SHANK3* gene due to a spectrum of anomalies in the terminal region of the long arm of chromosome 22, ranging from single-nucleotide variants to large deletions affecting multiple genes [1]. *SHANK3* is a key structural protein in excitatory synapses, with several isoforms with different functions in development and in the synapse [2, 3]. Deletions or sequence variants of the *SHANK3* gene are associated with the neuropsychiatric manifestations of the syndrome and required for the diagnosis of PMS [4–7]. Individuals with PMS often present with intellectual disability (ID), features of autism spectrum disorder (ASD), hypotonia, and severely delayed or absent speech [8–10]. Genotype-phenotype studies in individuals with terminal deletions have found that the severity of speech impairment and intellectual disability increases with increasing deletion size [8, 9]. In one recent study examining phenotypic manifestations among 17 individuals with sequence variants within *SHANK3* [7], the majority developed single words, and 44% had phrase speech, in contrast to more severe impairment in individuals with deletions.

Epilepsy is reported in 17% to 70% of individuals with PMS [9, 11–14]. As individuals with PMS age, they appear to be at increased risk for bipolar disorder [15–20] and an associated risk of significant cognitive and behavioral regression [5, 6, 16, 18–20]. Indeed, *SHANK3* variants have been implicated in the risk for severe neuropsychiatric disorders, including mood and psychotic disorders [15, 16, 19, 21, 22]. Gauthier et al. (2010) identified sequence variants in the *SHANK3* gene in four individuals initially diagnosed with atypical, early-onset schizophrenia, and a history of borderline to mild intellectual disability [21]. Catatonia, a unique syndrome of motor and autonomic dysregulation associated with a variety of psychiatric and medical conditions, has also been described in PMS [7, 15, 22, 23]. Of note, catatonia in pediatric populations and in individuals with developmental disabilities often goes unrecognized [24] and poorly treated [25].

A few previous cross-sectional studies have used systematic methods to characterize the behavioral profile of individuals with PMS across the lifespan [19, 26–28]. However, the nature and course of psychiatric symptoms in PMS, and in particular their association with regression occurring much later than the early childhood regressions typical of ASD, have not been extensively documented. In this retrospective study, we collected developmental histories, behavioral profiles, and genetic findings of 38 adolescents and adults with PMS and psychiatric illness with the aim to (1) better characterize the psychiatric and developmental phenomena reported in

PMS and (2) aid in early recognition and treatment optimization.

## Methods

### Participants and procedures

The study was approved by the Institutional Review Board of the PMS International Registry (PMSIR) (<https://www.pmsf.org/registry/>). Informed consent for participation in the Registry was obtained from the parents or legal guardians of participants, who also signed a release for inclusion in publication, and for integration of their interview data with their PMSIR data. Families were recruited by outreach through the PMS Foundation community Facebook page, and families were specifically invited to participate if the individual with PMS had experienced distinct psychiatric changes, such as mood episodes, psychosis, marked changes in sleep and energy, major loss of skills, sudden new intense obsessive-compulsive behaviors, or other neuropsychiatric difficulties, with or without regression. Families either contacted the researcher (TMK) directly in response to the Facebook message or responded after other families relayed the recruitment message on Facebook to parents with possible clinical concerns as described. In addition to the 37 English-speaking families, six families were referred through the PMS Spanish Association, and two enrolled and completed the study procedures.

Thirty-seven caregivers completed interviews on 39 participants and provided informed consent; one participant was excluded from the analysis since criteria were not met for a distinct psychiatric episode. Three families had responded to the invitation but did not complete interviews or consent after an initial contact established that they did not meet criteria for a distinct psychiatric episode. The final sample included 38 individuals from 36 families, ranging in age from 13 to 50 at the time of contact. The sample includes two sets of monozygotic twins with both twins enrolled. Caregivers interviewed were mothers in all but one case, in which the respondent was a sibling who was the legal guardian. Interviews were conducted in English ( $n = 34$ ) or Spanish ( $n = 2$ ), and respondents lived in the USA ( $n = 29$ ), Australia ( $n = 4$ ), Canada ( $n = 1$ ), England ( $n = 1$ ), Netherlands ( $n = 1$ ), and Spain ( $n = 2$ ).

### Measures

A semi-structured interview entitled the Caregiver Interview for Psychiatric Illness in Persons with ID (see Additional file 1) was developed by TMK and conducted with caregivers by child and adolescent psychiatrists (TMK for English interviews and MPT for Spanish interviews). The interview includes questions designed to elicit descriptions of the participant's developmental history, major health challenges, the emergence and course

of episodes of psychiatric illness or regression, response to pharmacologic treatment, and current level of functioning. Interviews typically lasted 90 min. All final notes were reviewed and approved by the families before inclusion in the study.

Genetic reports were obtained for all participants and reviewed by the geneticist (CB) curating results for the PMSIR. PMSIR data were used to confirm genetic results for study participants and for comparisons of prevalence of genetic variants, age, and gender. However, only 21 of 38 participants in this study had completed the PMSIR clinical and developmental questionnaires, limiting direct comparisons of clinical data between study participants and other Registry members. Nine of 38 participants were not enrolled in the Registry prior to study participation.

Comparisons between functional status and developmental milestones in study participants vs Registry data included parent report of whether key developmental skills were ever achieved on the Caregiver Interview (for the study sample) and on the Registry's Developmental Questionnaire for a group of respondents of similar age, with Registry data excluding the participants who were enrolled in the current study.

Assessment of behavioral symptoms and labeling of psychiatric diagnoses in the context of neurodevelopmental disorders is complicated by cognitive and communicative limitations, atypical presenting features, and premorbid characteristics (e.g., echolalia, repetitive behaviors). The Diagnostic and Statistical Manual for Mental Disorders, 5th edition [29] does not comprehensively include modifications of all diagnostic criteria for differential manifestations that may present in the context of intellectual disability, and there is a dearth of psychometrically rigorous instruments validated for psychiatric evaluation in this population. Therefore, we used the Diagnostic Manual - Intellectual Disability, Second Edition (DM-ID-2) [30] to classify psychiatric episodes. The DM-ID-2 is based on the DSM, adapted to include caregiver observations of behavior and to reduce the number of symptoms required to make diagnoses where persons with intellectual disability may not be able to report experiences [31]. All cases were reviewed by a child and adolescent psychiatrist (TMK) using a checklist of DM-ID-2 criteria for each of these disorders. The symptoms reported by caregivers during acute episodes met criteria for major depressive episode, manic episode, obsessive-compulsive disorder, generalized anxiety disorder, brief psychotic disorder, schizoaffective disorder, and catatonia associated with another mental disorder (see Additional file 2). In addition, two child and adolescent psychiatrists (MPT, AK) randomly reviewed and classified eight cases to assure accuracy of diagnostic classification. Agreement on the presence of a mood disorder

was 100%, agreement on whether the first mood episode was depressive or manic was 88%, and agreement on the presence of catatonia was 88%.

The word "regression" is often used to describe a wide variety of states, including transient loss of skills during psychiatric episodes with and without catatonia. For clarity, "regression" was defined in this study as a prolonged loss of previously acquired skills that either (a) began when the individual was psychiatrically well or (b) began during a psychiatric episode, with loss of skills persisting for at least 6 months beyond the resolution of the psychiatric episode.

## Results

Descriptive statistics and comparisons to participants in the PMSIR are reported in Table 1. Summaries of case histories and genetic findings are reported in Table 2. There was a strong female predominance in this sample (31 females, 7 males) whereas PMS typically affects males and females in equal proportion. There were 23 individuals with terminal deletions, with a mean size of 1.63 Mb (range 160 kb–6.41 Mb). Five deletions were secondary to a chromosomal rearrangement: a ring chromosome 22 in three individuals and an unbalanced translocation in two. Twelve individuals with terminal deletions had not had a karyotype, so the possibility of a ring chromosome 22 cannot be excluded. Fifteen individuals had pathogenic sequence variants in *SHANK3* (12 frameshift variants and 3 nonsense variants).

As compared with the 509 PMSIR registrants not in this study who had genetic data available, sequence variants in *SHANK3* were present at higher rates in our sample (39% [15/38] vs 6% [32/509]; Fisher's exact test,  $p = 4 \times 10^{-8}$ ), and conversely, terminal deletions were less frequent (61% [23/38] vs 92% [467/509]; Fisher's exact test,  $p = 8 \times 10^{-7}$ ). Comparisons with 130 PMSIR registrants of similar age with questionnaire data available are also reported in Table 1. In addition, deletions tended to be smaller in the participants of this study than in the PMSIR (mean size 1.634 Mb vs 3.633 Mb; unpaired two-tailed Student's *t* test,  $p = 0.0019$ ). In particular, individuals with small deletions, defined as those including at most the four distal genes, *ARSA*, *SHANK3*, *ACR*, and *RABL2B*, are over-represented among study participants compared to the PMSIR (57% [12/21 deletions with size information] vs 19% [72/387]; Fisher's exact test,  $p = 1.6 \times 10^{-4}$ ). (Heterozygous loss of *ARSA*, *ACR*, and *RABL2B* does not contribute to the PMS phenotype, so deletions including these genes are equivalent to deletions involving only *SHANK3*.)

## Developmental history

Although documentation of the severity of ID was not available, reported levels of adaptive functioning suggest

**Table 1** Demographic and clinical variables in the study sample as compared to the Phelan-McDermid Syndrome International Registry (PMSIR) participants 13 or older

	This study ( <i>n</i> = 38)	PMSIR ( <i>n</i> = 130)	Comparison
Mean age at data collection	24.7 years ± 9.92	20.8 years ± 7.65	$t(166) = 2.56, p = .011$ $\chi^2(1) = 10.21, p = .001$
Gender			
Male	18% (7/38)	47% (61/130)	$\chi^2(1) = 10.20, p = .001$
Female	82% (31/38)	53% (69/130)	
Genetic defect <sup>a</sup>			
Terminal deletion	61% (23/38)	91% (118/130)	$\chi^2(1) = 19.79, p < .001$
Interstitial deletion	–	2% (3/130)	
SHANK3 sequence variant	39% (15/38)	7% (9/130)	
ASD diagnosis (ever) <sup>d</sup>	55% (21/38)	41% (37/91 <sup>b</sup> )	$\chi^2(1) = 2.105, p = .147$
History afebrile seizure(s)	39% (15/38)	41% (37/91)	$\chi^2(1) = .044, p = .834$
Walked independently (ever)	100% (38/38)	81% (64/79 <sup>c</sup> )	$\chi^2(1) = 8.212, p = .004$
Spoke in phrases or sentences (ever)	79% (30/38)	51% (40/79)	$\chi^2(1) = 8.317, p = .004$
Toileted independently “always” or “sometimes” (ever)	89% (34/38)	48% (38/79)	$\chi^2(1) = 18.029, p < .001$
Dressed self independently (ever)	78% (30/38)	42% (33/79)	$\chi^2(1) = 13.26, p < .001$
Chronic constipation	84% (32/38)	15% (14/91)	$\chi^2(1) = 55.428, p < .001$
Acute urinary retention	47% (18/38)	3% (3/87)	$\chi^2(1) = 37.091, p < .001$

<sup>a</sup>Among all Registry participants (*n* = 509, excluding the study participants), there are 467 terminal deletions (92%), 10 interstitial deletions (2%) and 32 sequence variants (6%)

<sup>b</sup>91 participants in this age range (excluding the study participants) completed the Registry Clinical Questionnaire

<sup>c</sup>79 participants in this age range (excluding the study participants) completed the Registry Developmental Questionnaire

<sup>d</sup>Prior to the onset of neuropsychiatric illness, 42% (16/38) of participants had ASD diagnoses

that mild to moderate ID was common in this sample prior to the onset of psychiatric symptoms and regression and that these individuals were less impaired prior to their psychiatric illness as compared to the PMSIR reference sample (Table 1). Prior to the onset of psychiatric illness, study participants were significantly more likely than participants in the PMSIR sample to ever have walked independently, achieved toilet training, verbal expression with at least phrase speech, and independence with dressing.

### Psychiatric illness

Psychiatric difficulties began between ages 10 and 18 in the majority of cases (28/38; 74%). Psychiatric symptoms emerged between the ages of 7 and 10 years in 5/38 cases (13%), while 5/38 cases (13%) developed psychiatric symptoms between ages 21 and 32. Using the DM-ID-2, first episodes met criteria for a manic episode in 17/38 cases (45%) and for a depressive episode in 14/38 cases (37%). First episodes in the remaining cases included six (16%) with a mixture of mood and anxiety symptoms, and one case of disorganized, bizarre behavior that suggested a brief psychotic episode.

Most participants (27/38; 71%) had experienced a mood episode in the year before the study. The aftermath of acute episodes was associated with higher baseline levels of anxiety and irritability and with regression.

Subsequent psychiatric episodes were superimposed and caregivers clearly distinguished episodes from baseline states. First episodes ranged from 8 months to 35 years before study participation. Reported episode length varied from periods of days to months. Most cases (34/38; 89%) had multiple distinct episodes consistent with a mood disorder, including 12 of 38 (32%) with two to four distinct episodes, 6 of 38 (16%) with five to nine episodes, and 16 of 38 (42%) with more than ten episodes (see Table 2 for details). Few cases (4/38; 11%) reported only a single psychiatric episode; all four of these were within the 3 years prior to study participation.

Twenty-nine of 38 cases (76%) reported a manic episode at some point in their illness; 24 of 38 (63%) reported both manic and depressive episodes. Nineteen of 38 cases (50%) were reported to have had psychotic symptoms during an acute mood episode. One participant presented with both depressive and manic episodes and with psychosis in between mood episodes, suggesting schizoaffective disorder.

New anxiety symptoms accompanied mood episodes in the majority of participants (26/38; 68%). Six participants (16%) met criteria for obsessive-compulsive disorder at some point in the course of their illness. Four participants (11%) met criteria for generalized anxiety disorder. Only two participants (5%) had first episodes that were predominantly anxious.

**Table 2** Case summaries

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
Case 1 Female Age at time of study	Terminal deletion [89 kb] arr[hg]19j 22q13.33(51, 122,483-51,211,392)x1	Phrase speech Toilet trained Dressed self Fed self Independent for hygiene Read sight words Counted to 100	None noted	Age 14 First episode depressed with new tics, fecal smearing Then, OCD, new pica, manic episode and catatonia Three episodes	Age 14 Decreased speech Decreased eye contact New onset incontinence Unable to dress self Lost all academic skills	Mood episode in past year Four years since regression Minimal recovery Occasional meaningful speech and singing Intermittent feeding self with utensil
Case 2 Female Age 29 years 6 months	Mosaic terminal deletion and interstitial duplication [4.4 Mb] 46,XX; arr[hg]19j 22q13.2q13.31 (43,675,642-46,807,366)x3[0.65], 22q13.31q13.33(46,808, 071-51,197,838)x1[0.65]	Single words Toilet trained Pretend play with dolls	Program transition	Age 27 First episode depressed with catatonia Then new generalized anxiety disorder (GAD) One mood episode Ongoing GAD	Age 27 Decreased speech Incontinent Decreased independence in ADLs Decreased pretend play	Two years since mood episode Two years since regression No recovery
Case 3 Female Age 18 years 0 month	Terminal deletion-unbalanced translocation [207 kb] 46,XX; arr[hg]19j 3p26.3 (180,509-2,097,153)x3, 22q13.33(50,990,475-51, 197,838)x1	Spoke in full sentences Toilet trained Wrote simple text Used iPad	URI Beginning new school	Age 12 First episode OCD dx PANDAS Then depressed with new tics, tremors and posturing, Then mixed manic and depressed symptoms with new aggression, new anxiety at leaving house Four episodes (three mood)	Age 15 Decreased speech clarity Frequent urinary incontinence Decreased independence in ADLs	Mood episode in past year Three years since regression Moderate recovery Still unpredictably incontinent Speech improved, still dysfluent
Case 4 Female Age 22 years 3 months	Terminal deletion – ring 22 46,XX,r [22](p13q13.3).ish r [22](ARSA-)	Phrase speech Never toilet trained Dressed self with prompts Read some sight words Did puzzles	URI	Age 16 First episode depressive symptoms <sup>5</sup> Then manic symptoms with hand posturing and gait disturbance Three mood episodes	Age 16 Decreased speech Decreased response to environment Decreased orientation	Mood episode in past year Six years since regression Skills continue to deteriorate
Case 5 Male Age 36 years 1 month	Terminal deletion [106 kb] 46,XY; arr[hg]18j 22q13.33 (49,474,771-49,581,309)x1	Full sentences Toilet trained Dressed self Did all self-care Independent with own routines Able to return home from day program unassisted and to be home alone safely	Program transition	Age 28 First episode depressed Then new aggression which worsened to require two hospitalizations and placement in nursing care facility Three mood episodes	Age 30 Slowly regressed over several years Lost speech Decreased continence Lost ability to dress and shower Needs help with eating Moved slowly No longer can be left alone	No episode in past 3 years Six years since regression Moderate recovery Remains largely mute and uses single words or grunts Dependent for ADLs Regained some self-care skills Improved mood Incontinent at night
Case 6 Female Age 28 years	Terminal deletion [54 kb] arr[hg]19j 22q13.33(51, 123,491-51,178,264)x1	Spoke in full sentences Toilet trained Dressed self Made snacks	Pneumonia	Age 14 First episode depressed Then mania with complete insomnia for 12 days, catatonia,	Age 26 Sporadic incontinence Confused Couldn't read or write	Mood episode in past year Two years since regression No recovery

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-TR criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2,3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
11 months		Read simple books Wrote simple text		neuroleptic malignant syndrome and seizures Now ECT dependent 10+ mood episodes	Decreased hand skills Poor memory	
Case 7 Female 34 years 6 months	Terminal deletion – ring 22 46,XX,r [22](q13.3) with deletion of terminal 22q	Simple repetitive speech Toilet trained Dressed self with prompts Some sight words Some computer skills	None noted	Age 30 First episode depressed Then both manic and depressed episodes 10+ mood episodes	Age 30 Decreased vocalizations Frequent incontinence Decreased independence with dressing	Mood episode in past year Four years since regression Moderate recovery Vocalizes more Remains incontinent Feeds self but needs supervision for choking Needs help with dressing
Case 8 Female 36 years 3 months	Terminal deletion [106 kb] arr[hg18] 22q13.33 (49,475,238–49,581,309)×1	Phrase speech Toilet trained Dressed self with supervision Read simple words Played with dolls	None noted	Age 11 First episode manic symptoms Then mixed mood episodes 10+ mood episodes	Age 11 Steady developmental decline from age 11 Lost almost all language Incontinent Lost use of utensils No longer dresses self No play interests	No episode in past year 25 years since regression No recovery
Case 9 Female 43 years 1 month	Terminal deletion – ring 22 [2.1 Mb] 46,XX,r [22](p13q11.2); arr[hg19] 22q13.32q13.33 (49,056,457–51,179,671)×1	Spoke in full sentences Toilet trained Dressed self Independent for hygiene Active in programs	None noted	Age 32 Abrupt onset of stuporous catatonia with food phobia Then multiple manic and depressed episodes 10+ mood episodes	Age 32 Decreased speech Incontinent No longer able to dress self or bathe self	Mood episode in past year 12 years since regression Minimal recovery Decreased speech Intermittent incontinence Needs supervision for self-care
Case 10 Female 17 years 11 months	Sequence variant – Frameshift NM_033517.1:c.3424_3425delCT, p.Leu1142Valfs*153	Spoke in full sentences Toilet trained Dressed self and did most hygiene Read sight words Wrote name, familiar words, copied text	Menses Started at new school	Age 14 First had three peri-menstrual manic episodes followed by paranoia Then prolonged severe depression with catatonic features Then acute OCD with tics, posturing and choreiform movements Then mania with first seizure and catatonia, dx seronegative autoimmune encephalitis Six episodes (five mood episodes)	No lasting loss of skills	Mood episode in past year No regression
Case 11 Male	Sequence variant – Frameshift NM_033517.1:c.3679dupG,	Phrase speech Social and interactive Toilet trained	Gastro-enteritis	Age 12 First episode manic with agitation, new pica, new incontinence,	Age 12 Lost most language Less social and interactive	Mood episode in past year Two years since regression Minimal recovery

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
14	p.Ala1227Glyfs*69	Read sight words Typed from a model		destructive behavior, mutism, and catatonia Then OCD with agitation and aggression Five+ mood episodes	Incontinent Lost all academic skills New obsessional and repetitive behaviors	Rare speech and interaction now Still incontinent
Case 12	Sequence variant – Frameshift NM_033517.1:c.4906_4921dup16, p.Pro1641Leufs*58 dn	Spoke in full sentences Toilet trained Dressed and washed Read at 3rd grade level Math grade level through 9th grade Worked at supported job in library and in town hospital Balanced own checkbook	Menses Viral infections	Age 11 First episode mixed, with agitation, insomnia, cognitive dulling, posturing Then multiple mood episodes with catatonia 20+ mood episodes	Age 11 Gradual, with each episode lost skills, twice lost ability to walk, would regain some skills with therapies, still working and verbal to age 28; after a severe cold lost all speech, continence, self-care and many motor skills, cannot use hands (dystonic posturing at wrists)	No episode in past year 15 years since most severe regression No recovery
Case 13	Terminal deletion [1.23 kb] 46,XX, arr[hg18] 22q13.33 (49,468,254–49,591,415)x1	Spoke in full sentences Toilet trained Pulled on clothes Needed help with ADLs Read at 1st grade level Wrote and typed Used iPad	Strep infection Menses	Age 9 First episode complex tics and choreiform movements w/ high strep titers, dx PANDAS and resolved with antibiotics Then rage outbursts and peri-menstrual aggression Then depressive episode with severe anxiety and new generalized anxiety disorder 3+ mood episodes	No lasting loss of skills	No episode in past year No regression
Case 14	Sequence variant – Nonsense NM_033517.1:c.5008A > T, p.Lys1670* (this individual also has a likely benign missense variant in SHANK3, c.3872C > T, p.Ser1291Leu)	No speech, used PECS Toilet trained Fed self Used iPad Navigated internet Liked music	None noted	Age 15 First episode manic Then monthly manic episodes Then severe aggression requiring hospitalization and residential care 20+ manic episodes	Age 15 Lost toilet training Averse to touch Lost computer skills Lost social interest	No episode in past year 18 months since regression Moderate recovery of toileting, self-feeding, some computer skills
Case 15	Terminal deletion [43 kb] arr[hg18] 22q13.33(49,479,705–49,522,868)x1	Single words Never toilet-trained Could change own pull-up Dress self Drink from cup	School re-entry Possible URIs	Age 9 First episode manic Then manic spells with OCD behaviors Then depressed periods with new aggression 10+ mood episodes	Age 24 Lost ability to: Dress self Change pull-up Drink from cup	Three years since last episode Four years since regression No recovery
Case 16	Sequence variant – Frameshift arr[hg19] 22q13.33(51,121,452–51,197,838)x1	Spoke in full sentences Toilet trained Dressed self Read	Menses	Age 13 First episode manic with paranoia Then depressive episode	No lasting loss of skills	Mood episode in past year No regression



**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-TR criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
Case 17	Terminal deletion [4.3 Mb] arr[hg19] 22q13.31q13.33 (46,928,208-51,224,252)x1 dn	Pretend play Wrote in cursive Karate		with catatonia requiring ICU care and ECT Then recurrent manic episodes Five+ mood episodes		
Case 18	Terminal deletion [76 kb] arr[hg19] 22q13.33(51,121,452-51,197,838)x1	Single words or short phrases Toilet trained Dressed self Fed self Rode scooter	Menses	Age 13 First episode depressed with catatonia Then mania with urinary frequency and occasional incontinence, changes in gait and posture Four mood episodes	No lasting loss of skills	Mood episode in past year No regression
Case 19	Sequence variant – Nonsense NM_033517.1:c.1572C>A, p.Cys524*	Spoke in full sentences Toilet trained Dressed self Showered self Read at 3rd grade level Wrote sentences Used calculator Used iPhone to call/text friends	Possibly his increased awareness of deficits	Age 16 First episode mixed mood disturbance with sleepiness and irritability Then mania alternating with depression and severe aggression Three+ mood episodes	Age 16 Confused Needs constant supervision Cannot dry self Puts clothes on while still wet Decreased academic skills Urinary incontinence Lost interest in usual activities	Mood episode in past year Four years since regression No recovery
Case 20	Sequence variant – Frameshift NM_033517.1:c.4065_4066delTTG, p.Val11357Glyfs*4 dn	Spoke in full sentences Toilet trained Independent for ADLs and travel with school groups Reading at 3rd grade level Attended community college Competitive tennis Marathoner	School transition	Age 17 First episode manic with irritability, confusion, catatonia and new aggression Then multiple manic and depressed episodes Psychotic features occurring between mood episodes 20+ mood episodes	Age 17 Gradual, lost most speech Often incontinent Lost ability to perform ADLs Requires constant 1:1 supervision	Mood episode in past year 12 years since regression No recovery
Case 21	Sequence variant – Frameshift NM_033517.1:c.4065_4066delTTG, p.Val11357Glyfs*4 dn	Phrase speech Asked for needs Toilet trained Fed self	Strep infection	Age 14 First episode OCD with enuresis at night, aggression and sub-threshold manic symptoms Then similar episodes of OCD with manic symptoms Later diagnosis of autoimmune encephalitis Three+ mood and OCD episodes	Age 15 Decreased intelligibility Decreased toileting Decreased communication Decreased feeding self	Mood episode in past year Two years since regression Moderate recovery of speech clarity and toileting skills
Case 21	Sequence variant – Frameshift NM_033517.1:c.4065_4066delTTG, p.Val11357Glyfs*4 dn	Phrase speech Toilet trained Fed self	Strep infection	Age 14 First episode anxiety/OCD, transient inability to speak, then developed	Age 14 Slow onset Decreased toileting	Mood episode in past year Two years since regression Moderate recovery of

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
(twin of case 20)		Dressed self Read a few sight words Basic writing		mania Then diagnosed with PANDAS, Then catatonia Five+ mood episodes	Decreased communication Decreased orientation Decreased feeding self No longer writes name	communication and self-care skills Less improvement with academics
Case 22	Terminal deletion [62 kb] arr[hg18] 22q13.33(49,406,251-49,468,408)x1	Few single words Not toilet trained Needed help for dressing Fed self with utensils	None noted	Age 8 First episode manic, then depressive episodes 10+ episodes	No lasting loss of skills	Mood episode in past year No regression
Case 23	Terminal deletion [2.5 Mb] arr[hg18] 22q13.32q13.33(47,003,473-49,515,911)x1	Phrase speech with poor articulation Toilet trained Intact ADLs Read simple books Memory games Jigsaw puzzles Dot-to-dot coloring	None noted	Age 32 First episode depressed Then recurrent depressed episodes with severe anxiety, SIB Then mania with catatonia 10+ mood episodes	No lasting loss of skills	Mood episode in past year No regression
Case 24	Terminal deletion [69 kb] arr[hg19] 22q13.33(51,128,324-51,197,766)x1	Phrase speech Toilet trained Dressed self Fed self Read simple text Wrote at a second grade level	Puberty	Age 15 First episode agitation, OCD Then catatonia and depression Then manic episodes 10+ mood episodes	Age 18 Decreased urinary continence Decreased independence for ADLs Lost all academic skills	No episodes in past year 18 years since regression No recovery
Case 25	Terminal deletion – unbalanced translocation [6.0 Mb] 46,XX,der(22)t(22;acro)(q13.33;p12); arr[hg19] 22q13.31q13.33(45,156,254-51,197,725)x1	Single words Toilet trained Fed self Did chores	Multiple family health stressors High strep titers	Age 21 First episode depressed with agitation, photophobia, then catatonia, diagnosed PANDAS One episode	No loss of skills	No episode in 3 years No regression
Case 26	Sequence variant – Frameshift NM_033517.1:c.4649_4653dupGCAGC	Spoke in full sentences Toilet trained Dressed with assistance Fed self	Strep infection	Age 13 First episode manic with acute onset insomnia, tics, anorexia diagnosed PANDAS Then new pica, catatonia Then mutism and aggression associated with recurrence of manic symptoms 10+ mood episodes	Age 13 Lost language Decreased fine motor skills Decreased toileting Decreased utensil use Decreased interest in people and hobbies Destructive Sleep disrupted	Mood episode in past year Five years since regression Minimal recovery Slightly improved language and toileting Remains socially withdrawn Has not regained fine motor skills
Male 18	p.Pro1552Alafs*14 dn (based on the results of his monozygotic twin brother)	Read fluently Acted out plays Used computer with sophistication (e.g., booked travel)				

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2,3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
Case 27	Sequence variant – Frameshift NM_033517.1:c.4649_4653dupGCAGC	Phrase speech Toilet trained Needed help with dressing Fed self with fingers Used computer Few sight words	Strep infection	Age 13 First episode manic with acute onset insomnia, tics, anorexia diagnosed PANDAS Then depression and catatonia 10+ manic and depressed episodes	Age 13 Lost most language Incontinent Decreased feeding self Decreased interest in people, activities	Mood episode in past year Five years since regression Moderate recovery Has regained some fine motor skills and social interests; but not language and full continence
Case 28	Terminal deletion [70 kb] arr[hg19] 22q13.33(51,127,898-51,197,838)x1	Spoke in full sentences Toilet trained Independent with dressing and care Took own meds Black belt in karate	Menses	Age 16 Gradual onset aggression Then manic episodes with unsafe behaviors 10+ manic episodes	Age 18 Became confused about daily tasks and had trouble with self-care Language deteriorated Episodes of running away	Manic episode in past year Six years since regression Has recovered all skills
Case 29	Sequence variant – Frameshift NM_033517.1:c.3679dupG, p.Ala1227Glyfs*69 dh	Spoke in full sentences Toilet trained Dressed self Independent for hygiene Fed self Read at 2nd grade level	Menses Hashimoto's encephalopathy	Age 12 Gradual onset confusion and choking spells unrelated to food Then episodes of mania and OCD with catatonia and disorganized behavior and new behavior posing risk of accidental injury 10+ mood episodes	Age 12 Lost all adaptive skills, including continence and speech Lost all academic skills	Manic episode in past year Four years since regression Minimal recovery of relatedness and communication No recovery of academic skills Dependent for ADLs Requires constant supervision Appears to understand language but little speech Plays simple computer games
Case 30	Terminal deletion with interstitial duplication [6.4 Mb] 46,XX,del [22](q13.3); arr[hg18] 22q13.31(43,276,438-49,691,432)x1, 22q13.31(42,885,935-43,272,271)x3	Minimal language Toilet trained for urine in daytime Fed self with fork Could put on clothes if in correct position	Mycoplasma pneumoniae	Age 14 First episode depressed with catatonia Then OCD and manic symptoms Five+ mood episodes	Age 15 Lost daytime continence Lost interest in play and relatedness Decreased feeding self Decreased vocalization	Mood episode in past year Three years since regression Moderate recovery Has regained energy and vocalization, not daytime continence
Case 31	Terminal deletion [5.0 Mb] (5 Mb terminal deletion with the breakpoint at 22q13.31)	Spoke a few words Toilet trained Fed self Ambulatory	None noted	Age 14 First episode manic Then repeated mood episodes at intervals of five or more years Three+ mood episodes	Age 47 Loss of skills with each psychiatric episode; recovered each time until age 47, then lost all language Lost ability to walk Lost feeding skills	Two years since last mood episode; Two years since regression No recovery No language Incontinent Cannot stand or walk, has

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
Case 32	Terminal deletion [76 kb] 46XX; arr[hg]19	Spoke in full sentences Toilet trained Intact ADLs	None noted	Age 14 First episode anxiety/OCD Then mania	No loss of skills	difficulty maintaining sitting Cannot feed self Needs total care
Case 31	22q13.33(51,121,452-51,197,838)x1 dn	Planned recipes and cooked Worked with young children Ran with running group Volunteered at nursing home		Then depression with slow recovery over 2 years followed by severe mood cycling years later Three+ mood episodes		Mood episode in past year (resolving) No regression
Case 33	Terminal deletion [481 kb] arr[hg]18] 22q13.33(49,210,245-49,691,432)x1	Single words Never toilet trained Fed self	None noted	Age 7 First episode bizarre behavior with agitation, disorientation and insomnia (possible brief psychotic episode) Then OCD and new pica, followed by mania 10+ mood episodes	Age 16 Lost all meaningful speech; repeats words Unable to feed self, eats by lowering face to plate Unable to assist with dressing Lost all play Elopes frequently	Mood episode in past year 25 years since regression No recovery
Case 34	Terminal deletion [53 kb] arr[hg]19] 22q13.33(51,144,903-51,197,838)x1	Spoke in full sentences Toilet trained Fed self	Multiple social stressors	Age 14 First episode depressed with anorexia and incontinence Then mania and new pica Five+ mood episodes	Age 14 Decreased speech Decreased play Decreased dressing Decreased continence	No episode in past year Four years since regression Moderate recovery of language, self-care and play skills
Case 35	Sequence variant – Frameshift NM_033517.1:c.4086_234087delAC	Phrase speech with echolalia Toilet trained Fed self Poured milk Dressed self with assistance Needed help with ADLs Pretend play	Multiple social stressors	Age 12 First episode depressed with confusion, new incontinence and catatonia Then mania Three+ mood episodes	Age 12 Steady ongoing regression Lost all speech Incontinent Lost all self-care skills	Mood episode in past year 11 years since regression No recovery Requires constant supervision Only able to walk short distances with difficulty Cannot climb stairs
Case 36	Sequence variant – Frameshift NM_033517.1:c.4065_4066delTTG	Spoke in full sentences Toilet trained Dressed self Fed self Read sight words Used tablet Math at 1st grade level	Social stressors	Age 14 First episode catatonic with urinary retention, insomnia and pica; did not recognize family; paranoid One episode	Still recovering from first episode with catatonia; cannot yet determine new baseline or whether lost skills meet criteria for regression	Eight months since onset of psychiatric illness Continues to regain language, personality, and orientation Still not able to open and use hands for ADLs Intermittently incontinent

**Table 2** Case summaries (Continued)

Case #	Genetic defect	Level of functioning prior to onset psychiatric illness <sup>1</sup>	Reported possible triggering stressors	Age onset psychiatric illness; psychiatric diagnoses by DSM-IV-2 criteria; associated features; number of episodes	Age and areas of regression after onset psychiatric illness <sup>2, 3</sup>	Years since last psychiatric episode and regression; degree of recovery in that time and skills regained
Case 37	Sequence variant – Nonsense NM_033517.1:c.4333C > T, p.Gln1445* dn	Phrase speech Toilet trained Fed self Dressed self with assistance Imaginative play Wrote name Copied text Drew pictures	Menses End of school year	Age 15 First episode depressed with insomnia, severe separation anxiety, apathy, decreased speech and interaction, swallowing difficulties, and catatonia One mood episode	Age 15 Lost most speech Lost ability to chew food Increased dependence for ADLs Lost all academic skills Lost imaginary play	No episode in past year Two years since regression Moderate recovery Regained some speech Eats normally Mostly continent Continues to not have academic skills, drawing skills, or imaginary play skills
Case 38	Sequence variant – Frameshift NM_033517.1:c.2763delG, p.Pro922Argfs*34 dn	Spoke in full sentences Toilet trained Sociable	Menses UTI	Age 13 First episode hypomanic Then 2 years later manic with aggression, incontinence; anxiety, talking to self, compulsions, then catatonia Three manic episodes	Age 15 Lost all speech Lost ability to feed self Incontinent Decreased social interaction	No episode in past year One year since regression Substantial recovery Recovered language Recovered feeding Improved social interaction Continues with intermittent incontinence

**Abbreviations:** ADLs activities of daily living, *dn* de novo, *dx* diagnosis, *ECT* electroconvulsive therapy, *ICU* intensive care unit, *OCD* obsessive-compulsive disorder, *PANDAS* pediatric autoimmune neuropsychiatric disorder associated with streptococcus, *PECS* Picture Exchange Communication System, *UTI* urinary tract infection, *URI* upper respiratory tract infection

- <sup>1</sup> All were ambulatory and able to feed themselves with utensils prior to psychiatric illness
- <sup>2</sup> Cases 11, 14, 17, 22, 30, 33, and 35 had regression in speech, play, and social interaction before age 8, as well as subsequent regressions accompanying psychiatric illness at an older age
- <sup>3</sup> Regression defined as loss of skills that persisted at least 6 months after resolution of acute psychiatric episode
- <sup>4</sup> Regression occurred years after onset of psychiatric illness
- <sup>5</sup> "Symptoms" used when sub-threshold for diagnosis of either depressive or manic episode

Symptoms consistent with a diagnosis of catatonia associated with another mental disorder were reported in 20 of 38 cases (53%). Seven of the 20 (35%) were on neuroleptics at the time of emergence of catatonic symptoms. Cases with sequence variants in *SHANK3* met diagnostic criteria for catatonia significantly more often (12/15; 80%) than cases with terminal deletions (8/23; 35%) (Fisher's exact test,  $p = 0.009$ ).

### Regression

The interview explored both abilities lost and the degree of return of skills over time. Caregivers were asked which skills were lost, at what age, and which, if any, skills were regained. Seven of the participants (18%) had experienced regressions in early childhood affecting communication, social interaction, and/or imaginative play (five by age two, one at age four, one at age seven), but we do not elaborate on those early regressions in the current report. Analysis focused on the 25 of 38 cases (66%) who had regressions that began within the 3 years after the onset of psychiatric episodes. Most of these regressions (21/25; 84%) began within a year after the onset of psychiatric episodes and involved multiple domains of function. Descriptions of the areas of skill lost and recovery are summarized in Table 2, which includes developmental status in terms of speech, toilet training, ability to dress and wash self, academic skills, and vocational activities when present. Caregiver reports of recovery of skills ranged from continuing loss of further skills to complete return to baseline function before the onset of psychiatric symptoms. Overall, more than half of the participants who regressed in the 3 years after the onset of psychiatric illness reported minimal recovery (14/25; 56%).

Antecedents to the onset of psychiatric illness and regression were explored in the interview. Menstrual cycling was reported to play a triggering role in 11 of 31 (35%) of the females. Acute infections were suspected triggers in 11 of 38 cases (29%). Psychosocial stressors were suspected triggers in 10 of 38 cases (26%). Several participants reported differing antecedent stressors for different episodes.

### Co-morbid conditions

Only a quarter (9/38; 24%) of study participants was known to have PMS before the onset of psychiatric symptoms and associated regression. Sixteen cases (42%) had diagnoses of ASD before the onset of psychiatric symptoms and regression; five more received an ASD diagnosis after the onset of psychiatric illness and regression.

Fifteen of 38 cases (40%) reported one or more afebrile seizure. Eight of those 15 cases (53%) reported a seizure in the 2 years preceding the interview. Fifteen of 38 cases (40%) had weight loss of 10

to 25 kg accompanying psychiatric episodes. Chronic constipation, intermittent urinary incontinence, and episodes of acute urinary retention were prevalent in this sample, particularly as subjects aged. Chronic constipation was noted in 32 cases (84%), with episodes of acute urinary retention reported in 18 (47%). The discomfort associated with these conditions may lead to non-specific behaviors such as agitation, aggression, and self-injury in people with ID; these chronic symptoms were not coded as mood episodes. A small subset of subjects (4/38; 11%) had an immune-related disorder. Two participants (5%) were diagnosed with Hashimoto's thyroiditis, one of whom was diagnosed with Hashimoto's encephalopathy, and two participants (5%) had immunoglobulin deficiency, including one with common variable immunodeficiency.

### Therapeutic interventions

At the time of interview, 32 of 38 participants (84%) were receiving one or more psychiatric medications, with 14 of 38 (37%) receiving four or more psychiatric medications. More than half (21/38; 55%) took anticonvulsants; all of these had mood symptoms, while 12 also had a history of seizures. Over half (55%) were receiving neuroleptics. Benzodiazepines were used either regularly or on an as-needed basis in 16 of 38 cases (42%). Alpha agonists, beta-blockers, antihistamines, and trazodone were prescribed for sleep or aggression. Smaller numbers of participants were receiving selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, buspirone, lithium, cannabinoid oil, or n-acetylcysteine.

Full details of dosages and adjustments to treatment regimens in response to changing psychiatric status were inconsistently available and are therefore not reported. However, many parents kept extensive notes, and their reports of responses to medication trials suggest two patterns worth noting: (1) participants were reported to be sensitive to side effects from neuroleptics, with adverse events including extrapyramidal symptoms, worsening aggression and/or onset of catatonic symptoms reported in 14 of 30 cases (47%), while (2) seven of nine participants (78%) treated with SSRIs for depressive symptoms developed agitation, aggression, or other manic-like symptoms within weeks of the start of treatment.

Three individuals were treated with electroconvulsive therapy (ECT) for catatonia with reported significant benefit; two continue to require maintenance ECT (duration of treatment 18 months in one, > 8 years in the other) while the third discontinued after initial response due to agitation. One participant with recurrent catatonia on maintenance ECT was reported to have also benefited from intravenous immunoglobulin (IVIG) with improved cognition and motivation, but developed

aseptic meningitis and a rash after the fifth treatment, leading to discontinuation of IVIG.

Nine participants (26%) were reported to have received immunomodulatory treatments for diagnoses of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) syndrome or of autoimmune encephalopathy. Six were diagnosed with PANDAS syndrome on the basis of clinical symptoms and positive strep cultures or elevated titers. One participant was diagnosed with Hashimoto's encephalopathy, and two with seronegative autoimmune encephalitis. Treatments included (1) antibiotics, (2) IVIG, and/or (3) systemic anti-inflammatories such as nonsteroidal anti-inflammatory drugs, steroids, or rituximab.

In four of six cases diagnosed with PANDAS syndrome, parents reported that antibiotic treatment was effective in reducing or eliminating acute symptoms. The remaining two improved slowly; one also received IVIG and the other received lorazepam; these parents were not confident that antibiotics had played a role in recovery. Treatment for PANDAS symptoms did not appear to prevent future mood episodes or regression, as all but one of these cases went on to have further psychiatric episodes and some had later regressions. The one participant diagnosed with Hashimoto's encephalopathy continues to receive regular infusions of IVIG with steroids, as well as rituximab. The two participants with diagnoses of seronegative autoimmune encephalopathy receive monthly IVIG.

Eight females were on hormonal therapy to eliminate menstrual cycles and reduce associated mood symptoms. Non-pharmacological treatments varied widely by geographic location and age, with those still in school more likely to be receiving structured behavioral interventions. Data on past and current behavioral programs and therapies were not included in the interview.

## Discussion

This case series has characterized a subset of individuals with PMS who have episodic, severe neuropsychiatric illness, frequently beginning in adolescence or early adulthood, with major impacts on functional status. The symptoms and course of illness often closely resembled bipolar illness, with psychotic features almost exclusively present in the context of mood episodes. None of the participants in our sample presented with a primary psychotic disorder, such as schizophrenia. However, one participant presented with distinct psychotic and affective episodes characteristic of schizoaffective disorder. Using the DM-ID-2 criteria [30], all but one of the participants had either a mood disorder or an anxiety disorder, with multiple discrete periods of illness in all but four.

Several triggers were often reported as temporal antecedents to the onset of psychiatric changes. Biological triggers included infections and changes in hormonal status, while environmental factors included stressful life events. Similar patterns have been observed in other, more common neurogenetic syndromes, including Down syndrome [32], Williams syndrome [33], and 22q11.2 deletion syndrome [34].

It is critical to emphasize the high incidence of catatonic symptoms in this subset of individuals with PMS, as catatonia often goes unrecognized or undertreated in individuals with developmental disabilities [25, 35]. Recognition and treatment of both stuporous and hypermotoric catatonia is crucial, as symptoms can lead to life-threatening complications. Other genetic conditions involving copy number variants, such as 22q11.2 deletions [36], have also been associated with psychiatric symptoms and with catatonia. Similar to their use in treating catatonia in other conditions, benzodiazepines and ECT were used in this cohort with reported tolerability and effectiveness.

Regression has long been recognized in neurodevelopmental disorders such as ASD [37], but the triggers and mechanisms are not well understood, and the literature focuses largely on early childhood regression, especially as it relates to Rett syndrome [37–40]. Significant cognitive and behavioral regression has been documented in PMS [5, 6, 9, 15, 16, 18, 41]. Verhoeven et al. [20] have recently published on the course of illness of 24 adolescents and adults with PMS referred for evaluation and treatment of “challenging behaviors and unstable mood.” In that sample, there were five individuals with periodic catatonic symptoms, and four other individuals who developed progressive loss of skills in their third or fourth decade.

Two thirds (66%) of our sample described lasting regressions that began within 3 years of the onset of psychiatric illness. These regressions in communication, self-care, and motor functions left a subset of previously more capable individuals largely non-verbal, incontinent, and unable to dress or feed themselves. Many of these participants continue to experience episodic psychiatric illness in addition to developmental decline. Interestingly, a similar combination of rapid onset psychiatric disturbance with marked regression and catatonia has been described in Down syndrome [42, 43] and subsequently labeled “Down syndrome disintegrative disorder.” A recent case series [44] documented a role for immunotherapy in restoring function and stability in these individuals, although it is also recognized that cognitive decline in Down syndrome relates to amyloid precursor protein gene triplication [45–47]. Regression in PMS may be more common than in Down syndrome, and its potentially devastating impact warrants ongoing study of the natural history, mechanism, and targets for intervention.

Given the methodological limitations and sample selection bias in this study, we are unable to draw conclusions about the prevalence of psychiatric illness and/or regression among people with PMS. This study was also limited by the lack of standardized or validated tools to measure neuropsychiatric symptoms in severely developmentally disabled children and adults. However, within this self-referred subset of individuals with PMS whose caregivers identified psychiatric illness, we observed a distinct pattern of affective episodes, with onset typically in puberty, a strikingly high incidence of catatonic symptoms, and an association with substantial regression in the second through fourth decades of life. Of note, a recent literature review analyzed prior reports of 56 individuals with PMS with accompanying neuropsychiatric symptoms, and concluded that “clinicians and caregivers need to be vigilant for loss of skills and neuropsychiatric changes in adolescents and adults with PMS, including the development of bipolar disorder and catatonia” [48].

Individuals with PMS who present with new psychiatric symptoms require careful monitoring and cautious early intervention. Response to traditional psychiatric interventions is variable, and the role for immunomodulatory treatments and ECT in specific subsets of patients should be explored in future studies. The pattern of rapid and severe deterioration described in more than half of this group calls for further investigation to identify triggers and the underlying biology and to delineate possible strategies for prevention and timely intervention. While the current study does not allow for specific treatment recommendations, there is an urgent need for clinical trials to assess the efficacy of existing psychopharmacological treatments for psychiatric symptoms in PMS, in addition to developing novel, targeted therapeutics.

The preponderance of females in this sample (> 4:1) is notable and calls for replication. Sequence variants in *SHANK3* were also six times more common in this sample than in the PMSIR. These findings raise questions about whether psychiatric problems and regression disproportionately affect females and/or individuals with *SHANK3* sequence variants, in contrast to those with deletions. In addition, prior to the onset of psychiatric illness, most of the participants described herein were less severely impaired in their adaptive functioning than is reported in most studies of PMS. This finding is likely related to the high proportion of individuals with *SHANK3* variants and small deletions in this sample.

Further studies should attempt to clarify if psychiatric difficulties are actually more common in individuals who are more verbal and social and who have more intact adaptive functioning at baseline, or, whether this finding is the result of selection bias in our sample, as the majority of participants (76%) were only diagnosed with PMS after the onset of psychiatric symptoms.

Finally, our sample underscores the importance of genetic testing as part of the medical work-up for individuals with this presentation. Chromosomal microarray is recommended for the evaluation of all children with global developmental delay or intellectual disability [49]. In the setting of superimposed psychiatric illness or regression, chromosomal microarray should be considered as first tier testing, followed by sequencing of *SHANK3* if the microarray is unrevealing.

## Conclusion

This study confirms that individuals with PMS are at risk of developing severe neuropsychiatric illness in adolescence or early adulthood. In most cases, the symptoms appear consistent with the expression of bipolar disorder in individuals with intellectual disability, with catatonia noted as a common co-occurring condition. Triggers may include infections, changes in hormonal status, and stressful life events. Significant cognitive and behavioral regression beyond a baseline level of disability has been previously reported in PMS and accompanied the onset of psychiatric illness in a majority of the cases reported here. Our results must be interpreted with caution given the potential selection bias in recruitment, but it is clear that people with PMS may show a rapid and severe deterioration that requires careful monitoring and intervention. Our findings also highlight the relevance of genetic testing in the work-up of individuals with intellectual disability and acute psychiatric illness or regression. Future research is needed to clarify the prevalence and nature of psychiatric symptoms and regression among larger unbiased samples of individuals with PMS and to delineate any shared mechanisms with other neurodevelopmental disorders presenting with psychiatric illness and/or regression in adolescence or early adulthood. Identification of early clinical and biological markers would contribute to our understanding of the underlying neurobiology of these disorders and potentially aid in monitoring, early intervention, or prevention.

## Additional files

**Additional file 1.** Caregiver Interview for Psychiatric Illness in Persons with ID (CIPIPID)

**Additional file 2.** Adapted Diagnostic Criteria, DM-ID-2

## Abbreviations

ASD: Autism spectrum disorder; DM-ID-2: Diagnostic Manual - Intellectual Disability, Second Edition; ECT: Electroconvulsive therapy; ID: Intellectual disability; IVIG: Intravenous immunoglobulin; PANDAS: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections; PMS: Phelan-McDermid syndrome; PMSIR: Phelan-McDermid Syndrome International Registry



### Acknowledgements

We thank the families for their many contributions and the Phelan-McDermid Syndrome Foundation for its support.

### Funding

MPT receives research support from the National Institute of Health National Research Service Award Institutional Training Program (T32) and the Beatrice and Samuel A. Seaver Foundation. AT receives support from the Intramural Research Program of the National Institute of Mental Health (ZICMH002961). AK receives support from the National Institute of Neurological Disorders and Stroke (R01NS105845-01 and U54 NS092090-01) and from the Beatrice and Samuel A. Seaver Foundation.

### Availability of data and materials

The datasets analyzed in the current study are available at the PMS International Registry to authorized users (<https://www.pmsf.org/registry/>).

### Authors' contributions

TK and MPT collected the data. BL and CB performed the analyses of the PMS International Registry data. CB reviewed all genetic reports and performed analyses of the relationship between genetic results and clinical findings. All authors were involved in drafting or revising the manuscript, have read and agreed to its content, and are accountable for all aspects of the accuracy and integrity of the manuscript, in accordance with ICMJE criteria.

### Ethics approval and consent to participate

Informed consent was obtained for participants, who were enrolled in the Phelan-McDermid Syndrome International Registry (<https://www.pmsf.org/registry/>).

### Consent for publication

All participants signed a release for publication of results.

### Competing interests

AK receives research support from AMO Pharma and consults to Ovid Therapeutics, Takeda, 5 AM Ventures, sema4, and LabCorp. The other authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA. <sup>2</sup>Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>3</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. <sup>4</sup>Phelan-McDermid Syndrome Foundation, Osprey, FL, USA. <sup>5</sup>Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, Paris, France. <sup>6</sup>Neurodevelopmental and Behavioral Phenotyping Service, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.

Received: 31 May 2019 Accepted: 23 January 2020

Published online: 12 February 2020

### References

- Phelan K, Rogers RC, Boccuto L. Phelan-McDermid syndrome. In: Adam M, Ardinger H, Pagon R, Wallace S, Bean L, Stephens K, editors. *Gene Reviews*. Seattle: University of Washington; 1993.
- Wang X, Xu Q, Bey AL, Lee Y, Jiang YH. Transcriptional and functional complexity of Shank3 provides a molecular framework to understand the phenotypic heterogeneity of SHANK3 causing autism and Shank3 mutant mice. *Mol Autism*. 2014;5:30.
- Costales J, Kolevzon A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. *Neurosci Biobehav Rev*. 2016; 63:207–22. <https://doi.org/10.1016/j.neubiorev.2016.01.001>.
- Wilson H, Wong A, Shaw S, Tse W, Stapleton G, Phelan MC, et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. *J Med Genet*. 2003;40:575–84.
- Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nat Genet*. 2007; 39(1):25–7.
- Bonaglia MC, Giorda R, Beri S, de Agostini C, Novara F, Fichera M, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with phelan/mcdermid syndrome. *PLoS Genet*. 2011;7(7): e1002173.
- De Rubeis S, Siper PM, Durkin A, Weissman J, Muratet F, Halpern D, et al. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. *Mol Autism*. 2018;9(1):1–20.
- Sarasua SM, Boccuto L, Sharp JL, Dwivedi A, Chen CF, Rollins JD, et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. *Hum Genet*. 2014;133(7):847–59. [cited 2015 Jan 12]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24481935>
- Soorya L, Kolevzon A, Zweifach J, Lim T, Dobry Y, Schwartz L, et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. *Mol Autism*. 2013;4(1):18. [cited 2015 Jan 12]; Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3707861&tool=pmcentrez&rendertype=abstract>
- Kolevzon A, Angarita B, Bush L, Wang AT, Frank Y, Yang A, et al. Phelan-McDermid syndrome : a review of the literature and practice parameters for medical assessment and monitoring. *J Neurodev Disord*. 2014;6:39.
- Khan O, Zhou X, Leon J, Kessler R, Gaughan T, D'Souza P, et al. Prospective longitudinal overnight video-EEG evaluation in Phelan-McDermid Syndrome. *Epilepsy Behav*. 2018;80:312–20.
- Jeffries AR, Curran S, Elmslie F, Sharma A, Wenger S, Hummel M, et al. Molecular and phenotypic characterization of ring chromosome 22. *Am J Med Genet A*. 2005;137(2):139–47. [cited 2015 Jan 12]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16059935>
- Dhar SU, Del Gaudio D, German JR, Peters SU, Ou Z, Bader PI, et al. 22q13.3 Deletion syndrome: clinical and molecular analysis using array CGH. *Am J Med Genet Part A*. 2010;152(3):573–81. [cited 2015 Jan 12]; Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3119894&tool=pmcentrez&rendertype=abstract>
- Holder JL, Quach MM. The spectrum of epilepsy and electroencephalographic abnormalities due to SHANK3 loss of function mutations. *Epilepsia*. 2016;57(10):1651–9.
- Serret S, Thümmeler S, Dor E, Vesperini S, Santos A, Askenazy F. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. *BMC Psychiatry*. 2015; 15(1):107. Available from: <http://www.biomedcentral.com/1471-244X/15/107%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/25947967%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4428105>
- Denayer A, Van Esch H, De Ravel T, Frijns JP, Van Buggenhout G, Vogels A, et al. Neuropsychopathology in 7 patients with the 22q13 deletion syndrome: Presence of bipolar disorder and progressive loss of skills. *Mol Syndromol*. 2012;3(1):14–20. [cited 2015 Jan 12]. <https://doi.org/10.1159/000339119>.
- Verhoeven WMA, Egger JIM, Cohen-Snuij R, Kant SG, de Leeuw N. Phelan-McDermid syndrome: clinical report of a 70-year-old woman. *Am J Med Genet A*. 2013;161A(1):158–61. [cited 2015 Jan 12]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23166010>
- Vucurovic K, Landais E, Delahaigie C, Entroppe J, Schneider A, Leroy C, et al. Bipolar affective disorder and early dementia onset in a male patient with SHANK3 deletion. *Eur J Med Genet*. 2012;55(11):625–9. [cited 2015 Jan 12]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22922660>
- Egger JIM, Zwanenburg RJ, Van Ravenswaaij-Arts CMA, Kleefstra T, Verhoeven WMA. Neuropsychological phenotype and psychopathology in seven adult patients with Phelan-McDermid syndrome: implications for treatment strategy. *Genes Brain Behav*. 2016;15:395–404.
- Verhoeven WMA, Egger JIM, de Leeuw N. A longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan McDermid syndrome. *Eur J Med Genet*. 2019;103751. <https://doi.org/10.1016/j.ejmg.2019.103751>.
- Gauthier J, Champagne N, Lafrenière RG, Xiong L, Spiegelman D, Brustein E, et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. *Proc Natl Acad Sci*. 2010;107:7863–8.
- Breckpot J, Vercruyssen M, Weyts E, Vandevoort S, D'Haenens G, Van Buggenhout G, et al. Copy number variation analysis in adults with catatonia confirms haploinsufficiency of SHANK3 as a predisposing factor. *Eur J Med Genet*. 2016;59:436–43.
- Jungová P, Čumová A, Kramarová V, Lisyová J, Ďurina P, Chandoga J, et al. Phelan-McDermid syndrome in adult patient with atypical bipolar psychosis repeatedly triggered by febrility. *Neurocase*. 2018;24(4):227–30. <https://doi.org/10.1080/13554794.2018.1542007>.

24. Benarous X, Consoli A, Raffin M, Bodeau N, Giannitelli M, Cohen D, et al. Validation of the Pediatric Catatonia Rating Scale (PCRS). *Schizophr Res*. 2016;176:378–86.
25. Dhossche DM, Wachtel LE. Catatonia is hidden in plain sight among different pediatric disorders: a review article. *Pediatr Neurol*. 2010;43:307–15.
26. Soorya L, Leon J, Trelles MP, Thurm A. Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid syndrome. *Clin Neuropsychol*. 2018;32:1226–55.
27. Richards C, Powis L, Moss J, Stinton C, Nelson L, Oliver C. Prospective study of autism phenomenology and the behavioural phenotype of Phelan-McDermid syndrome: comparison to fragile X syndrome, Down syndrome and idiopathic autism spectrum disorder. *J Neurodev Disord*. 2017;9:37.
28. Zwanenburg RJ, Ruiters SAJ, Van Den Heuvel ER, Flapper BCT, Van Ravenswaaij-Arts CMA. Developmental phenotype in Phelan-McDermid (22q13.3 deletion) syndrome: a systematic and prospective study in 34 children. *J Neurodev Disord*. 2016;8:16.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Association.
30. Fletcher RJ, National Association for the Dually Diagnosed, & American Psychiatric Association. DM-ID: Diagnostic Manual Intellectual Disability : a clinical guide for diagnosis of mental disorders in persons with intellectual disability. Kingston: National Association for the Dually Diagnosed; 2007.
31. Fletcher RJ, Barnhill J, McCarthy J, Strydom A. From DSM to DM-ID. *J Ment Health Res Intellect Disabil*. 2016;9:189–204.
32. Dykens EM, Shah B, Davis B, Baker C, Fife T, Fitzpatrick J. Psychiatric disorders in adolescents and young adults with Down syndrome and other intellectual disabilities. *J Neurodev Disord*. 2015;7:9.
33. Valdes F, Keary CJ, Mullett JE, Palumbo ML, Waxler JL, Pober BR, et al. Brief report: major depressive disorder with psychotic features in Williams syndrome: a case series. *J Autism Dev Disord*. 2018;48:947–52.
34. Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, Van Den Bree MBM, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. *Am J Psychiatry*. 2014;171:627–39.
35. Fink M, Taylor MA, Ghaziuddin N. Catatonia in autistic spectrum disorders: a medical treatment algorithm. *Int Rev Neurobiol*. 2006;72:233–44.
36. Butcher NJ, Boot E, Lang AE, Andrade D, Vorstman J, McDonald-McGinn D, et al. Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: an overview and case series. *Am J Med Genet Part A*. 2018;176:2146–59.
37. Barger BD, Campbell JM, McDonough JD. Prevalence and onset of regression within autism spectrum disorders: a meta-analytic review. *J Autism Dev Disord*. 2013;43:817–28.
38. Thurm A, Powell EM, Neul JL, Wagner A, Zwaigenbaum L. Loss of skills and onset patterns in neurodevelopmental disorders: understanding the neurobiological mechanisms. *Autism Res*. 2018;11:212–22.
39. Gadow KD, Perlman G, Weber RJ. Parent-reported developmental regression in autism: epilepsy, IQ, schizophrenia Spectrum symptoms, and special education. *J Autism Dev Disord*. 2017;47(4):918–26.
40. Einspieler C, Marschik PB. Regression in Rett syndrome: developmental pathways to its onset. *Neurosci Biobehav Rev*. 2019;98:320–32.
41. Reiersen G, Bernstein J, Froehlich-Santino W, Urban A, Purmann C, Berquist S, et al. Characterizing regression in Phelan McDermid syndrome (22q13 deletion syndrome). *J Psychiatr Res*. 2017;91:139–44.
42. Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, Kishnani PS. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with down syndrome. *J Child Neurol*. 2015;30:1147–52.
43. Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. *Neuropsychiatr Dis Treat*. 2015;11:941.
44. Cardinale KM, Bocharnikov A, Hart SJ, Baker JA, Eckstein C, Jasien JM, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. *Dev Med Child Neurol*. 2018;61:847–51.
45. Lao PJ, Handen BL, Betthauser TJ, Mihaila I, Hartley SL, Cohen AD, et al. Alzheimer-like pattern of hypometabolism emerges with elevated amyloid- $\beta$  Burden in Down syndrome. *J Alzheimers Dis*. 2017;61:631–44.
46. Hartley SL, Handen BL, Devenny D, Mihaila I, Hardison R, Lao PJ, et al. Cognitive decline and brain amyloid- $\beta$  accumulation across 3 years in adults with Down syndrome. *Neurobiol Aging*. 2017;58:68–76.
47. Startin CM, Ashton NJ, Hamburg S, Hithersay R, Wiseman FK, Mok KY, et al. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. *Alzheimers Res Ther*. 2019;11(1):1–12.
48. Kolevzon A, Delaby E, Berry-Kravis E, et al. Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature. *Molecular Autism*. 2019: <https://doi.org/10.1186/s13229-019-029-3>.
49. Moeschler JB, Shevell M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics*. 2014;134:e903–18.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

